|
|
| (4 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Reteplase#How Supplied]] |
| {{Reteplase}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==How Supplied==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| Retavase® Kit - NDC 24477-041-02
| | [[Category: Anticoagulants]] |
| | |
| Retavase® Half-Kit - NDC 24477-040-01
| |
| | |
| Retavase®, is supplied as a sterile, preservative-free, lyophilized powder in 10.4 unit (equivalent to 18.1 mg Retavase®) vials without a vacuum, in the following packaging configurations:
| |
| | |
| '''Retavase® Kit''': 2 single-use Retavase® vials 10.4 units (18.1 mg), 2 single-use diluent vials for reconstitution (10 mL Sterile Water for Injection, USP), 2 sterile 10 mL syringes, 2 sterile dispensing pins, 4 sterile needles, 2 alcohol swabs and a package insert;
| |
| | |
| '''Retavase® Half-Kit''': 1 single-use Retavase® vial 10.4 units (18.1 mg), 1 single-use diluent vial for reconstitution (10 mL Sterile Water for Injection, USP), a sterile dispensing pin and a package insert.
| |
| | |
| ==Storage==
| |
| | |
| Store Retavase® at 2-25°C (36-77°F). The box should remain sealed until use to protect the lyophilisate from exposure to light. Do not use beyond the expiration date printed on the box.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = | accessdate = }}</ref>
| |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]] | |